This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
CGRP mAbs decrease headache days and improve disability in migraine patients.
Why it matters
CGRP mAbs represent a significant advancement in migraine treatment, addressing the need for more effective and safer options. This could lead to better management of a condition that affects many individuals.
How the study worked
The article is a narrative review summarizing recent advances in CGRP monoclonal antibody therapy for migraines.
What this study cannot tell us
The review does not provide new experimental data and relies on existing studies, which may vary in quality and scope.
Read the original research
Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review.
Saudi journal of medicine & medical sciences, 11(1), 11-18
Citation
Aditya, Suruchi; Rattan, Aditya. (2023). Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review.. Saudi journal of medicine & medical sciences, 11(1), 11-18. https://doi.org/10.4103/sjmms.sjmms_95_22